MASON, Ohio--(BUSINESS WIRE)--Jul. 29, 2020-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in several upcoming investor conferences.
AtriCure will be participating in the Guggenheim MedTech Disruptors Summit, scheduled to be held virtually August 10-11, 2020. AtriCure’s management is scheduled to present on Monday, August 10, 2020, at 10:00 a.m. Eastern Time.
AtriCure will be participating in the Canaccord Genuity 40th Annual Growth Conference, scheduled to be held virtually August 11-13, 2020. AtriCure’s management is scheduled to present on Thursday, August 13, 2020, at 9:00 a.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com.
AtriCure management will be participating in 1x1 meetings at the 5th Annual Needham Med Tech Conference, scheduled to be held virtually Monday, August 17, 2020.
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005104/en/
Chief Financial Officer
Lynn Pieper Lewis